证券代码：688298 证券简称：东方生物 公告编号：2025-053 浙江东方基因生物制品股份有限公司 关于自愿披露获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上述14种高危型HPV核酸检测及16/18分型试剂在国内取证，进一步丰富了公 司对HPV病毒检测的产品种类；新冠及甲乙流病毒核酸联检试剂在国内取证，进一 步完善了公司在国内呼吸道联合检测产品的布局，有利于应对常规季节性呼吸道 病毒感染的检测，以上两种产品的取证，拓宽了公司在国内分子诊断技术配套可 销售的产品种类，有利于国内市场的整体拓展。 三、风险提示 上述产品的实际销售业绩取决于产品的实际竞争力和市场销售能力，目前尚 无法预测对公司未来经营业绩的影响，敬请投资者注意投资风险。 特此公告。 浙江东方基因生物制品股份有限公司 董 事 会 浙江东方基因生物制品股份有限公司（以下简称"公司"）控股子公司杭州 丹威生物科技有限公司（以下简称"杭州丹威"）近日取得以下几款医疗器械产 品的注册证书，内容公告如下： | 产品名称 | 证书编号 | ...

Core Viewpoint - Dongfang Bio (688298.SH) announced that its subsidiary Hangzhou Danwei Biotechnology Co., Ltd. has obtained registration certificates for two medical device products, enhancing its product offerings in HPV and respiratory virus detection [1] Group 1: Product Development - The two newly registered products are: a nucleic acid detection kit for 14 high-risk types of human papillomavirus (HPV) and a combined nucleic acid detection kit for COVID-19 and influenza A and B viruses [1] - The HPV detection kit expands the company's product range for HPV virus testing in the domestic market [1] - The COVID-19 and influenza detection kit improves the company's portfolio in respiratory virus testing, addressing seasonal respiratory virus infections [1] Group 2: Market Expansion - The registration of these products broadens the company's sales offerings in molecular diagnostic technology, facilitating overall market expansion in China [1]

Core Viewpoint - The company, Dongfang Biological (688298.SH), announced that its subsidiary, Hangzhou Danwei Biotechnology Co., Ltd., has obtained registration certificates for two medical device products, enhancing its product offerings in HPV and respiratory virus detection [1] Group 1: Product Development - The two newly registered products are: a nucleic acid detection kit for 14 high-risk types of human papillomavirus (HPV) and a combined nucleic acid detection kit for COVID-19 and influenza A and B viruses, both using fluorescent PCR technology [1] - The registration of the 14 high-risk HPV nucleic acid detection kit expands the company's product range for HPV virus detection in the domestic market [1] - The COVID-19 and influenza virus detection kit enhances the company's portfolio in respiratory combined detection products, aiding in the detection of seasonal respiratory virus infections [1] Group 2: Market Expansion - The certification of these two products broadens the company's sales offerings in molecular diagnostic technology, facilitating overall market expansion in the domestic market [1]

Group 1 - The company announced the removal of Zhang Yidong as the employee representative supervisor and the election of Chen Yu as the employee representative director of the third board of directors [2] - The decision was made during the employee representative assembly held on September 15, where the representatives voted on the matter [2] - Chen Yu's term will last from the date of the election until the end of the current term of the third board of directors [2]

证券代码：688298 证券简称：东方生物 公告编号：2025-052 浙江东方基因生物制品股份有限公司 关于免去职工代表监事并选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2025 年 9 月 15 日，浙江东方基因生物制品股份有限公司（以下简称"公司"） 召开 2025 年第一次临时股东大会，审议通过关于《关于取消监事会并修订<公司 章程>的议案》，根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海 证券交易所科创板股票上市规则》及修订后的《公司章程》等相关规定，公司不 再设置监事会；公司董事会设职工代表董事一名。 根据相关规则，公司拟免去职工代表监事并选举职工代表董事。公司于同日 召开职工代表大会，经与会职工代表表决决定：免去职工代表监事职务，张奕东 先生不再担任东方生物职工代表监事；选举陈虞女士为公司第三届董事会职工代 表董事，任期自公司本次职工代表大会选举通过之日起至公司第三届董事会任期 届满之日止。 一、关于免去职工代表监事的情况说明 | 姓名 | 离任职 务 | ...

证券代码：688298 证券简称：东方生物 公告编号：2025-051 浙江东方基因生物制品股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 2、 公司在任监事3人，出席3人； 3、 公司董事会秘书章叶平女士出席了本次会议；公司高管均列席了本次会议。 （一） 股东大会召开的时间：2025 年 09 月 15 日 （二） 股东大会召开的地点：浙江省湖州市安吉县递铺街道阳光大道东段东方 基因会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 97 | | --- | --- | | 普通股股东人数 | 97 | | 2、出席会议的股东所持有的表决权数量 | 99,835,865 | | 普通股股东所持有表决权数量 | 99,835,865 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 52.16 ...

国浩律师（杭州）事务所 关 于 浙江东方基因生物制品股份有限公司 2025 年第一次临时股东大会 法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 法律意见书 致：浙江东方基因生物制品股份有限公司 国浩律师（杭州）事务所（以下简称"本所"）接受浙江东方基因生物制品 股份有限公司（以下简称"公司"）委托，指派律师出席公司 2025 年第一次临 时股东大会（以下简称"本次股东大会"），并依据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、中国证券监督管理委员会（以下简称"中国证监会"）发布的《上市 公司股东会规则》 ...

Summary of Key Points Core Viewpoint - On September 12, four listed companies conducted stock buybacks, indicating a trend of companies returning capital to shareholders and potentially signaling confidence in their future performance [2]. Group 1: Company Buyback Details - Dongfang Biological conducted the largest buyback, amounting to 22.11 million yuan, with a total of 820,000 shares repurchased [2]. - Great Wall Motors repurchased shares worth 13.53 million yuan, totaling 1.08 million shares [2]. - Qianwei Yangchu repurchased shares for 3.72 million yuan, with a total of 110,000 shares bought back [2].

Wind数据显示，9月12日，4家上市公司回购股票，其中东方生物回购金额最高达2211万元，回购数量 82万股，长城汽车回购金额达1353万元，回购数量108万股，千味央厨回购金额达372万元，回购数量11 万股。 ...

Core Viewpoint - Oriental Bio has faced significant operational challenges, including two consecutive years of losses and recent management changes, which have raised concerns about its future performance and strategic direction [1][2][3]. Financial Performance - Oriental Bio reported a dramatic decline in revenue, with 2023 revenue plummeting by 90.65% to 820 million yuan, and a net loss of 398 million yuan, marking a 119.23% year-over-year decrease [3][4]. - In 2021, the company achieved record revenues of 10.169 billion yuan, a 211.43% increase from the previous year, and a net profit of 4.92 billion yuan, reflecting a 193.33% growth [3]. - The company’s performance was heavily influenced by its COVID-19 testing products, which contributed significantly to its revenue during the pandemic [4]. Management Changes - The company has experienced a shift in its management team, with two board members resigning within a month, raising questions about leadership stability [1]. Business Expansion and Strategy - Oriental Bio is actively expanding its business, particularly in the U.S. market, through acquisitions and the establishment of production bases for chronic disease monitoring and animal diagnostics [5][6]. - The company has diversified its portfolio by adding an animal vaccine business, aiming to create a dual-track business model that includes both human and animal health [5]. Legal Challenges - The company is currently facing a significant lawsuit in the U.S., with claims exceeding 1 billion USD related to alleged contract violations, which could impact its financial stability [6]. Shareholder Actions - In response to ongoing losses and to bolster market confidence, Oriental Bio initiated a share buyback program, committing to repurchase shares worth between 25 million and 50 million yuan [7].